Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Seph M PalominoDepartment of Pharmacology, University of Arizona, 1501 N. Campbell Avenue Tucson, Tucson, AZ 85719, USA.
Aidan A LevineDepartment of Pharmacology, University of Arizona, 1501 N. Campbell Avenue Tucson, Tucson, AZ 85719, USA.
Erika Liktor-BusaDepartment of Pharmacology, University of Arizona, 1501 N. Campbell Avenue Tucson, Tucson, AZ 85719, USA.
Parthasaradhireddy TanguturiDepartment of Pharmacology, University of Arizona, 1501 N. Campbell Avenue Tucson, Tucson, AZ 85719, USA.ORCID 0000-0002-2566-9312
John M StreicherDepartment of Pharmacology, University of Arizona, 1501 N. Campbell Avenue Tucson, Tucson, AZ 85719, USA.
Tally M Largent-MilnesDepartment of Pharmacology, University of Arizona, 1501 N. Campbell Avenue Tucson, Tucson, AZ 85719, USA.ORCID 0000-0001-7599-102X
Funding
VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Jennifer Wright Bea · 1985 to 2026
$110.2M
The Center of Excellence in Addiction Studies (CEAS)P30DA051355 · NIDA · UNIVERSITY OF ARIZONA · PI PORRECA, FRANK, VANDERAH, TODD W · 2021 to 2025
$6.7M
Development of Hsp90 Isoform- Selective Inhibitors as a Novel Opioid Dose-Reduction TherapyR01DA052340 · NIDA · UNIVERSITY OF ARIZONA · PI STREICHER, JOHN MICHAEL · 2021 to 2025
$3.3M
Targeting the Endocannabinoid System for Headache InterventionR01NS126752 · NINDS · UNIVERSITY OF ARIZONA · PI Tally Marie Milnes · 2023 to 2026
$2.4M
Blood Brain Barrier and Migraine: Effect on Therapy (Diversity Supplement)R01NS099292 · NINDS · UNIVERSITY OF ARIZONA · PI MILNES, TALLY MARIE · 2017 to 2021
$1.7M
Primary Afferent Transmission in the Trigeminal Dorsal HornF32DE022499 · NIDCR · OREGON HEALTH & SCIENCE UNIVERSITY · PI MILNES, TALLY MARIE · 2011 to 2014
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Brain Hsp90 Inhibition Mitigates Facial Allodynia in a Rat Model of CSD Headache and Upregulates Endocannabinoid Signaling in the PAG. · full record | OpenQuestion